Drug Type CRISPR/Cas9 |
Synonyms- |
Target |
Action inhibitors |
Mechanism ATAD3A inhibitors(ATPase family AAA domain containing 3A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Squamous Cell Carcinoma of Head and Neck | Preclinical | United States | 01 Jun 2023 |





